Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

Table 4 Post-transplantation engraftment and responses in 39 patients with high-risk non-Hodgkin’s lymphoma

Parameter	R-CHOP (n = 14)	CHOP (n = 25)	P value
Time from APBSC infusion to WBC engraftment (days)^a	11 (9–13)	11 (8–14)	0.692
Time from APBSC infusion to PLT engraftment (days)^a	12.5 (7–18)	12.0 (9–32)	0.988
Duration of rhG-CSF support from APBSC infusion to engraftment (days)^a	8.5 (4–12)	7.0 (3–25)	0.410
CR for B-cell lymphoma [cases (%)]^b	14 (100)	4 (50)	0.010

APBSC autologous peripheral blood stem cells, rhG-CSF recombinant human granulocyte colony-stimulating factor; CR, complete response. Other abbreviations as in Tables 1, 2 and 3
^aThe values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses
^bAll the 14 patients in R-CHOP group and 8 patients in CHOP group had B-cell lymphoma

ISSN: 2523-3548